Navigation Links
Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits
Date:8/25/2008

C'elle Discovers Stem Cells Found in Menstrual Blood May Offer Long-Lasting

Therapeutic Effects for Time-Pressed Women

OLDSMAR, Fla., Aug. 25 /PRNewswire/ -- Time. It is a precious commodity. Yet most women would agree that there never seems to be enough of it. And the small amount of time a woman spends on doing something just for herself usually pales in comparison to the time she invests in others. This reality has led many women in need of quality time to seek out "quick fixes" at day spas, and most recently medical spas, where services and procedures can be costly. However, the benefits for these pricey treatments are usually fleeting, with no real long-lasting, therapeutic effects.

Now, thanks to the cutting-edge research and technology of C'elle, a service dedicated to providing women with a safe and easy method of collecting and preserving stem cells found in her menstrual fluid each month, a woman can do something positive for herself while also potentially helping her family.

In fact, the latest science has revealed that stem cells, harvested from a woman's own menstrual blood may be used in treating a number of possibly life-threatening diseases that she, a parent, a sibling or even her children may face in later years, such as osteoporosis, heart disease, stroke, Alzheimer's and Parkinson's disease.

With C'elle's affordable collection process, menstrual cells are processed and cryo-preserved (stored at a very low temperature) for potential cellular therapies that may emerge in the future. These self-renewing cells one day may even be utilized for cosmeceutical treatments, such as anti-aging therapies or sports medicine.

"C'elle offers women the unique opportunity to bring the focus back on themselves in a way that is lasting and long term without being time-consuming or invasive," said Michelle Fox Kay, Director of Marketing for C'elle. "We live in a society where women do not have a lot of time to spare on doing something healthful for themselves, and unfortunately, this can negatively impact the way a woman handles her health today and in the future. C'elle gives women the tools necessary to do something proactive that may affect her, and possibly her family, in the long run."

For more information about C'elle, please call 1-877-892-3553 or visit http://www.celle.com.

About Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL)

Based in Oldsmar, Florida, with over 155,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit http://www.cryo-cell.com.


'/>"/>
SOURCE C'elle
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
2. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
3. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
4. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
5. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
6. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
7. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
8. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
9. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... and clinical outcomes, today released the podcast, “Make Plans for MACRA,” ... value-based payment into the physician's office and how physicians and other clinicians are ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president ... honored by Enterprising Women magazine as one of its 2017 Enterprising Women of ... owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively support ...
(Date:4/26/2017)... JOHYNSTON, Iowa (PRWEB) , ... April 26, 2017 ... ... agriculture? DuPont Pioneer today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates ... plants and help farmers produce more and better food, with fewer resources. It ...
(Date:4/25/2017)... San Jose, CA (PRWEB) , ... April 25, ... ... in cross-screen access, support, and collaboration, announces Mirroring360 Pro . This new ... providing a comprehensive collaboration experience for education and business. , Mirroring360 Pro enables ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
Breaking Medicine News(10 mins):